Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of HRS-4029 injection in acute ischemic stroke
CTR20262921Phase 2Active
- Sponsor
- Beijing Shengdi Pharmaceutical
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4029 in ischemic stroke, sponsored by Beijing Shengdi Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
HRS-4029
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20262921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262921.